Get the Stockscreener App
8.42
6.13%
-0.55
After Hours:
8.36
-0.06
-0.71%
Novavax Inc stock is traded at $8.42, with a volume of 4.10M.
It is down -6.13% in the last 24 hours and up +8.65% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$8.97
Open:
$8.97
24h Volume:
4.10M
Relative Volume:
0.91
Market Cap:
$1.37B
Revenue:
$1.08B
Net Income/Loss:
$422.82M
P/E Ratio:
3.693
EPS:
2.28
Net Cash Flow:
$-637.33M
1W Performance:
+6.99%
1M Performance:
+8.65%
6M Performance:
-0.71%
1Y Performance:
+7.54%
1-Day Range:
$8.25
$9.19
1-Week Range:
$7.845
$9.276
52-Week Range:
$5.01
$10.64
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.42 | 1.46B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Why institutional investors increase stakes in Novavax Inc. (NVV1) stockWeekly Market Outlook & Entry and Exit Point Strategies - mfd.ru
The Truth About Novavax Inc (NVAX): Comeback Story or Total Bag Fumble? - AD HOC NEWS
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance Singapore
Human Vaccine Adjuvants Market Forecast with Size and Share Analysis 2026 to 2035 - Insightace Analytic
Novavax, Inc. (NVAX) Investor Outlook: Exploring a Potential 48.15% Upside in the Biotechnology Arena - DirectorsTalk Interviews
Allianz Asset Management GmbH Acquires 872,987 Shares of Novavax, Inc. $NVAX - MarketBeat
(NVAX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
RSI Check: Is Novavax Inc a defensive stockMarket Rally & Reliable Price Breakout Signals - baoquankhu1.vn
Market Review: Is Novavax Inc a defensive stockProduct Launch & Verified Momentum Stock Watchlist - baoquankhu1.vn
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax rises after a seven-day slide - MSN
Novavax, Inc. (NVAX) Stock Analysis: Assessing a 48% Potential Upside Amidst Market Challenges - DirectorsTalk Interviews
Why Novavax (NVAX) Dipped More Than Broader Market Today - Yahoo Finance
Pfizer Taps Novavax Matrix-M To Refresh Vaccine Growth Story - Yahoo Finance
Pfizer Reshapes Portfolio With Metsera Deal Novavax Pact And R&D Push - simplywall.st
Pfizer Q4 Earnings Preview: Analysts Expect Decline - Intellectia AI
Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
Earnings Update: Can Novavax Inc stock outperform in a bear marketJuly 2025 Sector Moves & Free Reliable Trade Execution Plans - baoquankhu1.vn
Novavax COVID-19 vaccine approved by the FDA - MSN
Weekly Earnings: Is Novavax Inc a turnaround storyGap Down & Accurate Technical Buy Alerts - baoquankhu1.vn
AI Stocks: Whats the beta of Novavax Inc stockPortfolio Value Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets - Finviz
Novavax (NASDAQ:NVAX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
9 High Growth Small Cap Stocks That Are Profitable - Insider Monkey
Moderna Vs. Novavax: 2 Pandemic Vaccine PioneersWhich Offers Better Value Today? (MRNA) - Seeking Alpha
Assessing Novavax’s (NVAX) Valuation After Its New Matrix M Licensing Agreement With Pfizer - Sahm
Pfizer Balances Vaccine Expansion And Drug Discounts With Novavax And TrumpRx - Yahoo Finance
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy? - Finviz
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy? - The Motley Fool
Pfizer Inks $530M Deal for Novavax Matrix-M Adjuvant Technology to Boost Vaccine Pipeline - Finviz
Here's Why Novavax (NVAX) Fell More Than Broader Market - Yahoo Finance
Why Is Pfizer Stock Rising Tuesday? - Sahm
Has Novavax cracked the code for survival in the vaccine arena? - PharmaVoice
Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Analysts - MarketBeat
Pfizer Reshapes Pipeline With Novavax Deal And ViiV Exit - simplywall.st
Responsive Playbooks and the NVAX Inflection - Stock Traders Daily
Novavax rises after licensing deal with Pfizer - MSN
Novavax, Inc. (NVAX) Stock Analysis: Exploring a 33.84% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
What's Driving the Market Sentiment Around Novavax Inc? - Benzinga
MRNA vs NVAX: Which vaccine stock is Wall Street more bullish on right now? - MSN
Novavax (NASDAQ:NVAX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Assessing Novavax (NVAX) Valuation After Pfizer Licensing Deal For Matrix M Adjuvant - Sahm
Decliners Report: Is Novavax Inc a play on infrastructure spendingRate Hike & Safe Entry Momentum Tips - baoquankhu1.vn
Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy? - Yahoo Finance
Reassessing Novavax (NVAX) After Recent Share Price Rebound And Valuation Signals - Yahoo Finance
Novavax grants license for use of Matrix-M adjuvant to Pfizer - MSN
Novavax (NVAX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Novavax Pfizer Licensing Deal Puts Matrix M And Valuation In Focus - Sahm
Key facts: Novavax signs $30M deal with Pfizer; shares rise 19.7% - TradingView — Track All Markets
Novavax, Inc.'s (NASDAQ:NVAX) Price Is Right But Growth Is Lacking After Shares Rocket 46% - 富途牛牛
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):